End organ damage

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Retrieved on: 
Tuesday, October 3, 2023
Vaccine, Infection, EU4, EXPEC Advanced Research Center, Diabetes, Sepsis, Hospital, Public, Clinical trial, End organ damage, Cancer, Escherichia coli, Research, Risk, AMR, USD, Science, Incidence, JAMA Network Open, Janssen Pharmaceuticals, Patient, ROW, Prevalence, Magnetic resonance, Global Burden of Disease Study, Mortality, Johnson & Johnson, Health, IED, Lancet, Kidney disease, Pharmaceutical industry, Poultry farming, Janssen, Sanofi

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Key Points: 
  • Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
    Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease (IED) annually, worldwide1,2
    Phase 3 clinical trial of vaccine candidate ongoing.
  • Sanofi announces today that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase 3.
  • Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults3.
  • Antimicrobial resistant (AMR) E. coli strains are an ongoing healthcare concern, with extraintestinal pathogenic E. coli a major driver behind the global AMR crisis4.

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Retrieved on: 
Monday, September 25, 2023
Heart, Male, Tacrolimus, University, Heart failure, Clinical trial, EGFR, End organ damage, University of Maryland Medical Center, Research, Plasma protein binding, History, Thumbay Hospital, Maryland School, Transplant, MD, Patient, Risk, Organ transplantation, Immune system, University of Maryland School of Medicine, Kidney transplantation, Immunosuppression, CD40L, Pharmaceutical industry, Dentistry, Eledone massyae

IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40 antibody, was used as a cornerstone component of the chronic immunosuppressive regimen administered following the second-ever transplant of a genetically modified heart from a pig to a human. The procedure was completed on September 20th at University of Maryland Medical Center on a 58-year-old male suffering from heart failure.

Key Points: 
  • IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40 antibody, was used as a cornerstone component of the chronic immunosuppressive regimen administered following the second-ever transplant of a genetically modified heart from a pig to a human.
  • The procedure was completed on September 20th at University of Maryland Medical Center on a 58-year-old male suffering from heart failure.
  • “The historic procedure we conducted on our courageous patient brings us to a pivotal moment in the history of organ transplantation.
  • Strategies to better and more safely protect transplanted organs and thus increase how long they function represent a significant area of unmet need in organ transplantation.

Scene Health & The Research Institute at Nationwide Children’s Hospital Secure $1.9M in NIH Funding to Pursue Improvements in Sickle Cell Disease Care and Outcomes

Retrieved on: 
Tuesday, September 19, 2023
Technology, Biotechnology, Audio, Video, Health, Consumer, Apps, Applications, Pharmaceutical, Research, Teens, Software, Children, Hospitals, Science, Clinical Trials, Partnership, Nationwide Children's Hospital, SBIR, Scene, SCD, National Heart, Lung, and Blood Institute, End organ damage, Quality of life, Small Business Innovation Research, Medicine, Cell, Lung, Pain, DOT, Patient, Sickle cell disease, Research institute, Hospital, Caregiver, Nationwide, Birth control, Hydroxycarbamide

Sickle cell disease hurts, and the debilitating pain can send children to the hospital multiple times a year.

Key Points: 
  • Sickle cell disease hurts, and the debilitating pain can send children to the hospital multiple times a year.
  • Today, Scene Health and the Research Institute at Nationwide Children's Hospital announced a $1.9 million effort to help children and teenagers living with sickle cell disease (SCD) improve their health and quality of life through increased adherence to hydroxyurea treatment.
  • The Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute will fund the ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) study.
  • With Scene's collaboration, the ADHERE study is poised to optimize video DOT's ability to promote lasting adherence.

National transplant patient and physician groups ask President Joe Biden and HHS Secretary Xavier Becerra to: "Stop private contractors from rolling back Medicare coverage of non-invasive blood tests to detect transplant rejection"

Retrieved on: 
Thursday, September 21, 2023
Trauma, DNA, Gift, CMS, Society, HHS, Centers for Medicare & Medicaid Services, The Wall Street Journal, International Society for Heart and Lung Transplantation, Anxiety, Lung transplantation, International Society of Sculptors, Painters and Gravers, Health, End organ damage, Multimedia, LCD, USC, Gene expression profiling, Government, Lung, GEP, Patient, Democrat, American Society of Transplantation, Kidney, Heart failure, House, Center for Medicare and Medicaid Innovation, International Society, Pelvic floor dysfunction, United States Department of Health and Human Services, Transplant surgeon, Pharmaceutical industry, Health insurance, Dentistry, Medicare, MD, Transplant, Policy, D.C

WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, along with other allied leaders across the transplant field, held a press conference, calling on President Joseph R. Biden and Health and Human Services (HHS) Secretary Xavier Becerra to stop the current attempt by private contractors to rollback Medicare coverage of safe, non-invasive molecular blood tests that can allow for the early detection of organ rejection.

Key Points: 
  • -- Paul Conway, AAKP
    Medicare coverage for these innovative blood tests became available for transplant patients starting in 2006, with coverage expanding in 20171.
  • The alternative for such blood tests is surgical biopsy procedures, which are more expensive, riskier, and burdensome.
  • See statements from American Society for Transplant Surgeons , American Society of Transplantation , and The International Society for Heart and Lung Transplantation .
  • This billing article was issued without allowing for public comment, including comments from the transplant patients who would be impacted.

Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Retrieved on: 
Monday, September 11, 2023
Vaccine, Interim, Senior, Virulence, Bronchopneumonia, American Society for Microbiology, European Society of Clinical Microbiology and Infectious Diseases, Infection, End organ damage, MD, Disease, Mortality, Congress, Society, Pharmaceutical industry

WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract describing the global in-progress Phase 2 study of CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development as an adjunct to antibiotic therapy for the treatment of severe community-acquired bacterial pneumonia (“SCABP”), has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”). This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance. The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.

Key Points: 
  • This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance.
  • The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.
  • “We are pleased to have the opportunity to present additional details of the CAL02 study in progress to our esteemed colleagues,” stated Valentin Curt, MD, Senior Vice President, Clinical Drug Development and Interim Chief Medical Officer at Eagle Pharmaceuticals.
  • “Inclusion at this scientific congress supports the significance of the potential clinical value of CAL02 to address a large, unmet medical need.

Reliq Health Technologies, Inc. Expands into Pediatric Remote Monitoring, Expects to Add 3,000 New Pediatric Patients in TX by Q2 2024

Retrieved on: 
Thursday, September 7, 2023
ER, State, Medicaid, WKN, Diabetes, Friends, Frankfurt Stock Exchange, Health care, Cardiovascular disease, TSX Venture Exchange, End organ damage, Quality of life, Hypertension, Patient, TMX Group, OTC, TSX, Health, Nerve, RHT, Family, Nursing

The Company expects to add over 3,000 pediatric patients in Texas to its iUGO Care platform by Q2 2024 through its existing contracts with home health agencies in the State.

Key Points: 
  • The Company expects to add over 3,000 pediatric patients in Texas to its iUGO Care platform by Q2 2024 through its existing contracts with home health agencies in the State.
  • These vulnerable young patients can benefit greatly from in-home monitoring of their chronic conditions to identify potential complications, enable early interventions and prevent hospitalizations.
  • Pediatric patients in particular have better health outcomes and report better quality of life when they are able to receive care in the home, surrounded by family and friends.
  • iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

Carling Adrenal Center Spotlights Pheochromocytoma: The Common Adrenal Tumor You've Never Heard Of--But Could Be Making You Sick

Retrieved on: 
Wednesday, August 23, 2023
Pheochromocytoma, Heart, Headache, Travel, Prevalence, Gland, End organ damage, Para, Neoplasm, Anxiety, Glomus tumor, Research, Brain, Paraganglioma, Blood, Anesthesia, Patient, Standard of care, Perspiration, Diagnosis, Hospital, MBSA, Disease, Pharmaceutical industry

Pheochromocytoma is a tumor that originates in the adrenal glands , situated above the kidneys.

Key Points: 
  • Pheochromocytoma is a tumor that originates in the adrenal glands , situated above the kidneys.
  • The founder of the Carling Adrenal Center, Dr. Tobias Carling , has spent decades dedicated to refining surgical techniques, research, and raising awareness about pheochromocytoma.
  • Dr. Carling and the Carling Adrenal Center team operate exclusively at the Hospital for Endocrine Surgery in Tampa, Florida.
  • The Hospital for Endocrine Surgery is home to the Carling Adrenal Center, Clayman Thyroid Center , and Norman Parathyroid Center .

Sickle cell disease is rife in west Africa - a fresh approach is needed to combat it

Retrieved on: 
Monday, August 7, 2023
People, Projection screen, Review, Genotype, Prevalence, Democratic Republic of the Congo, National Health Insurance Scheme (Ghana), Anemia, Hydroxycarbamide, African, Pharmacy, Leg, Research, Social media, Plant, Development, Anti-transglutaminase antibodies, US, Health, Dizziness, Publication, Democratic republic, Population, Patient, End organ damage, Income, Sickle cell disease, Genetic testing, Diagnosis, Mortality, Knowledge, Ulcer, Death, Family, National Health Insurance Scheme, Safety, Fatigue, Disease, Pharmaceutical industry, Vaccine, Whaling, Hospital, Health insurance

Sickle cell disease refers to a group of inherited blood disorders with symptoms like anaemia and blocked blood vessels.

Key Points: 
  • Sickle cell disease refers to a group of inherited blood disorders with symptoms like anaemia and blocked blood vessels.
  • About 80% of the world’s sickle cell disease cases occur in sub-Saharan Africa.
  • Reports indicate that about 25% of Nigerians carry the gene that causes it and 2% to 3% of the population suffer from sickle cell disease.
  • We propose premarital genotype screening and comprehensive health insurance coverage for all sickle cell disease patients.

Gaps in the management of sickle cell disease

    • The review provided insight on relevant medical interventions and helped to identify prospects for overcoming the burden of sickle cell disease.
    • Niprisan has also proven to be effective in the management of sickle cell disease.
    • A review of 55 publications found that access to comprehensive management of sickle cell disease was lacking.
    • A lack of adequate knowledge about sickle cell disease in countries like Nigeria, DR Congo, Cameroon and Nigeria contributed to the high prevalence of the condition.
    • Health insurance can be an invaluable tool that can help ease the financial burden associated with the management of sickle cell disease.

Saving West African lives

    • Campaigns aimed at improving relevant knowledge, alongside pre-marital screening and counselling, could significantly reduce the prevalence of the disease in West Africa.
    • One idea could be to use public figures such as musicians, actors and social media celebrities in public awareness campaigns.
    • Given the high prevalence of sickle cell disease in the region, the continent should lead initiatives to end the disease.
    • Strategies to prevent, reduce, eliminate and manage the disease have to be integrated and pursued aggressively.

MDbio – The Doctors BrandTM Publishes New Article About Artificial Intelligence in Healthcare

Retrieved on: 
Monday, July 24, 2023
Learning, Natural language processing, CT, Radiation, Health, Doctor, Deep learning, Fear, End organ damage, Intelligence, Brain, Lupus, School, MRI, Patient, Machine learning, Blood, Artificial intelligence, AI, Medical device, Medical imaging

Beverly Hills, California, July 24, 2023 (GLOBE NEWSWIRE) -- MDbio – The Doctors BrandTM published a new article about artificial intelligence in healthcare and what the future of this industry could look like.

Key Points: 
  • Beverly Hills, California, July 24, 2023 (GLOBE NEWSWIRE) -- MDbio – The Doctors BrandTM published a new article about artificial intelligence in healthcare and what the future of this industry could look like.
  • This article carefully analyzes what this technology can do and how it could benefit the healthcare industry practically.
  • There is also an in-depth analysis of how AI in healthcare can help medical professionals learn more about the major opportunities presented by artificial intelligence.
  • According to MDbio, AI health can have a positive impact by making it easier for doctors to make diagnoses.

Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)

Retrieved on: 
Monday, July 24, 2023
Vaccine, Liposome, Infection, Tissue, Interim, Patent, Mechanics, Virulence factor, Senior, Virulence, QIDP, Bronchopneumonia, End organ damage, Bacterial pneumonia, AB toxin, Eagle, Inflammation, The Lancet, Sepsis, United States patent law, Patient, Standard of care, Physician, NCE, Medicine, Disease, Mortality, Genetically modified bacteria, Nursing care plan, Health, FDA, Death, Pneumonia, Safety, Pharmaceutical industry

The Phase 2 study plans to enroll approximately 276 patients with SCABP at more than 100 sites in over 20 countries worldwide.

Key Points: 
  • The Phase 2 study plans to enroll approximately 276 patients with SCABP at more than 100 sites in over 20 countries worldwide.
  • In addition, depending upon recruitment rates, Eagle anticipates having its first 50% interim report around the first quarter of 2024.
  • CAL02 is a novel first-in-class broad-spectrum anti-virulence agent being developed as an add-on to standard of care treatment of SCABP.
  • In August 2021, Eagle entered into a worldwide licensing agreement with Combioxin SA for the commercial rights to CAL02.